Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05145816 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
A Phase 1 study of Amyloidosis and AL Amyloidosis, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 3
- Study locations
NCT05145816 is a Phase 1 study of Amyloidosis and AL Amyloidosis that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 37 participants, below the 1,128-participant average among 28 other Amyloidosis trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05145816, a Phase 1 study of Amyloidosis and AL Amyloidosis, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this study is to test the safety of drug, Belantamab Mafodotin, and see what effects (good and bad) it has on people who take it and have amyloidosis, and to determine the most effective dose of the drug. The study will have 2 phases (parts). The first phase of the study will test different doses of Belantamab Mafodotin. The second phase will test Belantamab Mafodotin at the dose level found to be safe and effective in phase 1
Conditions Studied
Interventions
- DRUG Belantamab mafodotin 2.5 mg/kg (8 weeks)
- DRUG Belantamab mafodotin 1.9 mg/kg (8 weeks)
- DRUG Belantamab mafodotin 1.4 mg/kg (12 weeks)
- DRUG Belantamab mafodotin 1.9 mg/kg (12 weeks)
- DRUG Belantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosages
Study Locations (3)
Tennessee
- Vanderbilt Ingram Cancer Center - Nashville
Texas
- UT Southwestern Medical Center - Dallas
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2024-02-15 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05145816
The ClinicalTrials.gov registry entry for NCT05145816 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,128-participant average among 28 other Amyloidosis trials with a reported enrollment target (97% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Amyloidosis appearing as the primary indexed condition, and to 5 interventions - of which Belantamab mafodotin 2.5 mg/kg (8 weeks) is the first listed.
NCT05145816 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Tennessee, Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT05145816 about?
NCT05145816 is a clinical study titled "Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis". The goal of this study is to test the safety of drug, Belantamab Mafodotin, and see what effects (good and bad) it has on people who take it and have amyloidosis, and to determine the most effective dose of the drug. The study will have 2 phases (parts). The first phase of the study will test diffe...
What is the current status of trial NCT05145816?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2024-02-15. Estimated completion is 2026-09-01.
What conditions does trial NCT05145816 study?
This clinical trial studies the following conditions: Amyloidosis, AL Amyloidosis.
What interventions are being tested in trial NCT05145816?
The interventions under investigation include: Belantamab mafodotin 2.5 mg/kg (8 weeks) (DRUG), Belantamab mafodotin 1.9 mg/kg (8 weeks) (DRUG), Belantamab mafodotin 1.4 mg/kg (12 weeks) (DRUG), Belantamab mafodotin 1.9 mg/kg (12 weeks) (DRUG), Belantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosages (DRUG).
Who is sponsoring clinical trial NCT05145816?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05145816 being conducted?
This trial has 3 study locations across Tennessee, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
RECRUITING · Phase 1
-
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
RECRUITING · Phase 1
-
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
ACTIVE NOT RECRUITING · Phase 1
-
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
COMPLETED · Phase 1
-
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
RECRUITING · Phase 2
-
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.